Amryt Pharma Share Discussion Threads

[dynamoo] 15/11/2016 09:58

No answer on a postcard for papillon, just a post here.It's sliding because the market is looking ahead 6 months to a year.Simple. They don't have funds to get this through all the upcoming hurdles (even with what's in bank now) so it's being priced in.Placement at some point soon is guaranteed. At what price? The market is good at determining that level. Less than 14p it seems to think.

[jacksonpollack] 15/11/2016 09:12

Heading for an all time low.

[icebreaker] 15/11/2016 08:40

Maybe I'm naive, but there must be something going on at the company. I have no idea what, as presumably the phase 3 study is now fully outsourced, but I am reluctant to accept that our executive team that appear on the web-site are sat there doing absolutely nothing!

We must have appointed a marketing director for a reason (not just because he was available). There must therefore be a plan to generate income in the interim!

[papillon] 14/11/2016 23:20

pottermagic2310 you could make the same "How is this a viable Business when it's just set-up to keep paying Employees at all levels for another 2 years with no plans to generate Income or a return for Shareholders ?" comment about the majority of AIM companies. It definitely applies to oil exploration companies such as PVR. PVR, like many AIM O&G's has no revenue stream; others do have a revenue stream, such as EOG, but often not enough revenue to compensate for their running and exploration costs.

AMYT has a small revenue stream, but not enough to compensate for it's running and drug trial costs. That's the name of the game, pottermagic2310, for most AIM commodity explorers and drug developers. Surely you must have realised that when you invested in AMYT? If you didn't then you must be very ignorant!

Nothing has changed for AMYT prospects since it's placing at 24p apart from a much lower share price Surely you must recognise that? The future for AMYT depends on whether it's successful, or not, with it's drugs undergoing (or about to undergo) trials. That isn't going to happen overnight. You have 3 alternatives as a small shareholder in AMYT: they are 1/ Sell your shares if you think they will continue to fall, 2/ hold for the phase 3 result, or 3/ buy more if you think they are cheap.

Me? I'm going to stick my shares in the proverbial bottom draw for the time being and await good news; that may come in what remains of 2016, 2017, or 2018. I might add a few more; I'm watching the share price closely.

[buffythebuffoon] 14/11/2016 21:36

It's amazing how many people who claim to be invested here just do not understand the investment proposition.

Buffy

[pottermagic2310] 14/11/2016 21:16

The problem with this now is that there's no Plan at all for the next 12 months to market any Products that might 'earn a crust' to offset Business costs. We only hear about marketing one key Product from 2019 and that additional Funds will definitely be needed from 2017 year-end.
How is this a viable Business when it's just set-up to keep paying Employees at all levels for another 2 years with no plans to generate Income or a return for Shareholders ?
Feeling quite pessimistic about this now
:-(

[papillon] 14/11/2016 17:59

Will July's low provide support or is it a case of it's going further down the plughole? Not a good short term investment; will AMYT fare better in the longer term? Answers on a postcard please! LOL.

PS. Regarding "TENDRARA!!!!", JP. If you were so confident of it's success why didn't you sell your FAST shares and buy SOU shares with the proceeds? Perhaps because you knew that 9 out of 10 exploration wells drilled FAILS!! Unfortunately, JP, you are only wise with the benefit of hindsight! We can all be successful investors with the benefit of hindsight! Unfortunate, but true!

[bigwavedave] 14/11/2016 10:41

Funding issue answered here:

[jacksonpollack] 09/11/2016 17:31

Interviews mean nothing.

[bigwavedave] 09/11/2016 16:55

Interview with the CFO on voxmarkets

[timbo003] 07/11/2016 18:18

 

See link to a new Proactive interview with Rory Nealon (COO) following the granting of orphan status to AP102 for Acromegaly





.....and a link below to the Wiki page on Acromegaly





 
 

 

[buffythebuffoon] 07/11/2016 14:34

Come on JP....you must be able to put a negative spin on that.

Buffy

[cpap man] 07/11/2016 07:55

RNS out from AMYT this morning....



Joe Wiley, CEO, commented:



"We are pleased that our drug compound, AP102, has received orphan drug designation from the FDA. AP102 has the potential to treat acromegaly, a rare disorder which is estimated to affect four to 13 in every 100,000, and causes excess growth of body tissue.



We believe that AP102 has the potential to improve outcomes for patients facing this debilitating disease and receiving the FDA's orphan drug designation marks an important regulatory milestone for Amryt as we prepare to bring AP102 into the clinic next year."

[pottermagic2310] 04/11/2016 21:59

Indeed... no idea why that incorrect address was published where I found it ??
This looks alot better...

[icebreaker] 04/11/2016 19:45

The registered office of my business is my accountant - as is common practice. The Amryt site says their Dublin Office is Fitzwilliam Place, Dublin.

[deckav] 04/11/2016 19:04

Fyi Potter. It's one of the most expensive areas of Dublin. Plenty of good businesses and embassies in that immediate area including the US embassy 100 meters down the road.

[pottermagic2310] 04/11/2016 18:59

Here's the registered Office of AMRYT (formerly FASTNET)...



106b Pembroke Road, Ballsbridge, 4, Ireland

Doesn't look much like a Business premises to me and from the look of the Cars parked locally, doesn't look like too many 'well-healed' Business People live/work in that Street either. Make of that what you will ????

[jacksonpollack] 04/11/2016 17:08

Looks like another aim con.

[icebreaker] 04/11/2016 16:34

Well I certainly wont be buying any more!

I think the lack of concern for their shareholders speaks volumes. If they met with the FDA as they reported they would, why haven't they reported back - there must have been something newsworthy to come from it. If they haven't yet met with them, why say they are due to meet with them early in Q4. We are no longer early Q4.